| Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study. | |
| | |
MedLine Citation:
|
PMID: 18442311 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Fracture efficacy of PTH and alendronate (ALN) is only partly explained by changes in BMD, and bone collagen properties have been suggested to play a role. We analyzed the effects of PTH(1-84) and ALN on urinary alphaalpha/betabeta CTX ratio, a marker of type I collagen isomerization and maturation in postmenopausal women with osteoporosis. In the first year of the previously published PaTH study, postmenopausal women with osteoporosis were assigned to PTH(1-84) (100 microg/d; n = 119), ALN (10 mg/d; n = 60), or PTH and ALN together (n = 59). We analyzed patients on ALN alone (n = 60) and a similar number of patients assigned to PTH alone (n = 63). During the second year, women on PTH in the first year were reallocated to placebo (n = 31) or ALN (n = 32) and women with ALN continued on ALN. During the first year, there was no significant change in alphaalpha/betabeta CTX ratio with PTH or ALN. At 24 mo, there was a marked increase of the alphaalpha/betabeta CTX ratio in women who had received PTH during the first year, followed by a second year of placebo (median: +45.5, p < 0.001) or ALN (+55.2%, p < 0.001). Conversely, the alphaalpha/betabeta CTX ratio only slightly increased (+16%, p < 0.05) after 2 yr of continued ALN. In conclusion, treatment with PTH(1-84) for 1 yr followed by 1 yr of placebo or ALN may be associated with decreased type I collagen isomerization. The influence of these biochemical changes of type I collagen on bone fracture resistance remains to be studied. |
| | |
Authors:
|
Patrick Garnero; Doug C Bauer; Emmanuel Mareau; John P Bilezikian; Susan L Greenspan; Clifford Rosen; Dennis Black |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research Volume: 23 ISSN: 1523-4681 ISO Abbreviation: J. Bone Miner. Res. Publication Date: 2008 Sep |
Date Detail:
|
Created Date: 2008-08-18 Completed Date: 2008-10-28 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 8610640 Medline TA: J Bone Miner Res Country: United States |
Other Details:
|
Languages: eng Pagination: 1442-8 Citation Subset: IM |
Affiliation:
|
INSERM Research Unit 664, Lyon, France |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Alendronate / pharmacology, therapeutic use* Biological Markers / metabolism Bone and Bones / drug effects, metabolism Collagen Type I / chemistry*, urine Female Humans Isomerism Middle Aged Osteoporosis, Postmenopausal / drug therapy*, urine Parathyroid Hormone / pharmacology, therapeutic use* Placebos |
| Grant Support | |
ID/Acronym/Agency:
|
MO1-RR000056/RR/NCRR NIH HHS; N01-AR-9-2245/AR/NIAMS NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Collagen Type I; 0/Parathyroid Hormone; 0/Placebos; 66376-36-1/Alendronate |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Current socio-economic measures, and not those measured during infancy, affect bone mass in poor urb...
Next Document: Prevention of trabecular bone loss induced by estrogen deficiency by a selective p38alpha inhibitor.